{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:28:58Z","timestamp":1786649338142,"version":"build-2736575974"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Malignant peritoneal mesothelioma (MPM) is a rare malignancy originating from the peritoneal serosa and is the second most common site of mesothelioma after the pleura. Localized disease presents as a focal circumscribed mass, whereas diffuse disease is usually associated with ascites and may metastasize to abdominal and pelvic lymph nodes. Cytoreductive surgery with heated intraperitoneal chemotherapy has been shown to improve progression-free survival and overall survival. Systemic chemotherapy with pemetrexed and platinum-based chemotherapy has also demonstrated a good treatment response. Recently, there has been an increased interest in the use of immune checkpoint inhibitors in the treatment of MPM. We present the case of a 59-year-old female with progressively worsening abdominal pain and constipation, who on further evaluation was found to have a huge MPM (17.3 \u00d7 17.1 \u00d7 13.3 cm) extending into the pelvic cavity with associated compression of the vagina, sigmoid colon, and ureters complicated by bilateral hydronephrosis. The tumor was deemed unresectable, and the patient was started on dual immunotherapy with ipilimumab and nivolumab. The patient had symptomatic improvement and a reduction in tumor size to 15.1 \u00d7 11 \u00d7 8.6 cm. Despite the initial response, the disease progressed (15.6 \u00d7 13.8 \u00d7 23.8 cm) and the patient ultimately succumbed to it. This case highlights the unique presentation of a massive localized MPM and emphasizes the need for further research to optimize treatment strategies.<\/jats:p>","DOI":"10.4103\/jcrt.jcrt_247_24","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T11:00:33Z","timestamp":1751713233000},"page":"739-742","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A giant peritoneal mesothelioma extending to the pelvic floor: A case report and review of the literature"],"prefix":"10.4103","volume":"21","author":[{"given":"Mathew","family":"Thomas","sequence":"first","affiliation":[{"name":"Department of Geriatrics, Yale New Haven Hospital\/Yale University, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harikrishnan","family":"Nandakumar","sequence":"additional","affiliation":[{"name":"Division of Thoracic Imaging and Intervention, Department of Radiology, Massachusetts General Hospital\/Harvard University, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parth","family":"Sampat","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, State University of New York (SUNY) Upstate Medical University, Syracuse, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Graziano","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, State University of New York (SUNY) Upstate Medical University, Syracuse, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,5]]},"reference":[{"key":"R1-20250707","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1148\/rg.282075175","article-title":"From the archives of the AFIP:Primary peritoneal tumors:Imaging features with pathologic correlation","volume":"28","author":"Levy","year":"2008","journal-title":"Radiographics"},{"key":"R2-20250707","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.amjms.2022.07.008","article-title":"Malignant peritoneal mesothelioma","volume":"365","author":"Chun","year":"2023","journal-title":"Am J Med Sci"},{"key":"R3-20250707","doi-asserted-by":"crossref","first-page":"392","DOI":"10.4103\/ijpm.ijpm_360_21","article-title":"STRN-ALK rearranged malignant peritoneal mesothelioma\u2014Presenting with bilateral extensive pelvic masses in a young woman:Mimicking low-grade serous ovarian carcinoma","volume":"66","author":"Bulutay","year":"2023","journal-title":"Indian J Pathol Microbiol"},{"key":"R4-20250707","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1245\/ASO.2006.05.041","article-title":"Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy:Results of a prospective study","volume":"13","author":"Brigand","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"R5-20250707","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/jso.24248","article-title":"What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy:A 25-year experience with 1,125 procedures","volume":"113","author":"Passot","year":"2016","journal-title":"J Surg Oncol"},{"key":"R6-20250707","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/PAS.0000000000001545","article-title":"Malignant mesothelioma of the peritoneum in women:A clinicopathologic study of 164 cases","volume":"45","author":"Malpica","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"R7-20250707","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3816\/CLC.2005.n.020","article-title":"Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma:Outcomes of an expanded access program","volume":"7","author":"J\u00e4nne","year":"2005","journal-title":"Clin Lung Cancer"},{"key":"R8-20250707","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743):A multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"R9-20250707","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE):A multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"R10-20250707","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1):An open-label, non-randomised, phase 2 study","volume":"6","author":"Calabr\u00f2","year":"2018","journal-title":"Lancet Respir Med"},{"key":"R11-20250707","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1158\/2159-8290.CD-21-0331","article-title":"Efficacy, safety, and biomarker analysis of combined PD-L1 (atezolizumab) and VEGF (bevacizumab) blockade in advanced malignant peritoneal mesothelioma","volume":"11","author":"Raghav","year":"2021","journal-title":"Cancer Discov"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_247_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:52:33Z","timestamp":1786647153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_247_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_247_24","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2024-01-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}